Anti-TNF-α therapies, particularly monoclonal antibodies, have demonstrated promising effects in reducing inflammation and tumor progression, but the emergence of resistance mechanisms underscores the need for improved therapeutic strategies. This evidence concerns the gene TNF and neoplasm.